Results 21 to 30 of about 116,020 (268)
Biomarker series: KRAS- A narrative review
Cancer Research, Statistics, and Treatment, 2021 Non-small cell lung cancer (NSCLC) has emerged as the poster child of molecular medicine. Kirsten rat sarcoma (KRAS)-mutated NSCLC is a common yet heterogeneous entity with distinct clinical and prognostic characteristics.
Ullas Batra, Shrinidhi Nathany
doaj +1 more source
KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations [PDF]
Genes & Cancer, 2011 KRAS is a potent oncogene and is mutated in about 30% of all human cancers. However, the biological context of KRAS-dependent oncogenesis is poorly understood. Genetically engineered mouse models of cancer provide invaluable tools to study the oncogenic process, and insights from KRAS-driven models have significantly increased our understanding of the ...
Rónán C, O'Hagan, Joerg, Heyer
openaire +2 more sources
Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy
Chinese Journal of Lung Cancer, 2022 Proteolysis targeting chimeria (PROTAC) degrades target proteins by utilizing the ubiquitin-proteasome pathway, subverting the concept of traditional small molecule inhibitors.
Lin JIANG +4 more
doaj +1 more source
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy [PDF]
Molecular Cancer, 2019 Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the development of resistance to currently available therapeutic interventions. Development of a new class of anticancer agents that directly targets KRAS may provide a more attractive option for the treatment of KRAS-mutant lung cancer.Here we identified a small molecule ...
Ke Xu +8 more
openaire +3 more sources
KRAS-G12C in the crosshairs [PDF]
Nature Reviews Cancer, 2019 Two papers report the discovery and preclinical analyses of two different covalent inhibitors of KRAS-G12C (AMG 510 and MRTX849) as well as the first data on the efficacy of these inhibitors in cancer patients.
openaire +2 more sources
ANALYSIS OF MUTATIONS IN KRAS AND BRAF GENES IN COLORECTAL CANCER IN RUSSIAN PATIENTS
Сибирский онкологический журнал, 2016 Mutations in KRAS and BRAF genes in 80 colorectal cancer (CRC) samples from Russian patients were tested using two methods: 1) allele-specific real-time PCR (as-rt PCR) and 2) wild-type blocking PCR with Sanger sequencing (WTBS).
E. E. Pisareva +3 more
doaj +1 more source
Somatic mutation testing: the role in differential diagnosis of thyroid neoplasms [PDF]
Эндокринная хирургия, 2019 Background: In the preoperative diagnosis of thyroid tumors the cytological examination of the material of fine needle aspiration biopsy is the gold standard and serves as the basis for planning of treatment strategy.
Vera A. Kachko +5 more
doaj +1 more source
PolitejaThe article is devoted to the Financial Stability Committee, which bridged the institutional gap that emerged after the 2008 crisis. The purpose of the paper is to analyse its institutional and legal capacity for macro-prudential supervision.
Ireneusz Kraś
doaj +1 more source
Targeting ST2 expressing activated regulatory T cells in Kras-mutant lung cancer
OncoImmunology, 2020 Oncogenic KRAS-mutant lung cancers remain treatment refractory. A better understanding of the immune response of KRAS-mutant lung cancers is required to facilitate the development of potential therapeutic strategies.
Byung-Seok Kim +3 more
doaj +1 more source
KRAS as a Therapeutic Target [PDF]
Clinical Cancer Research, 2015 Abstract KRAS proteins play a major role in human cancer, but have not yielded to therapeutic attack. New technologies in drug discovery and insights into signaling pathways that KRAS controls have promoted renewed efforts to develop therapies through direct targeting of KRAS itself, new ways of blocking KRAS processing, or by ...
openaire +4 more sources